Dasgupta, Santanu, Ph.D.
- PhD in Cancer Biology, Chittaranjan National Cancer Institute, India.
- Postdoctoral Fellowship: Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine.
Breast Cancer, Mitochondrial Genomics, Cancer Biomarkers.
- Characterization of key molecular genetic alterations in Breast Cancer.
- Defining the role of miRNAs and mitochondrial genetic alteration in Breast Cancer.
- 2002-Scholar-In-Training Award from American Association for Cancer Research.
- 2007- Scholar-In-Training Award from American Association for Cancer Research.
- 2008-US-Egypt Joint Science and Technology Award.
- 2011- A.D. Williams Award, Virginia Commonwealth University.
- 2012- Elsa U Pardee Foundation Award.
American Association of Cancer Research
Breast cancer is the most common malignancy among women worldwide, causing half a million death annually. Invasive ductal carcinoma of the milk duct (IDC) represents up to 90% of all the breast cancers. Abnormal expression of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) has been linked to a subset of breast cancers. However, an increasing number of patients do not express HER2, ER or PR and are known as triple negative breast cancer (TNBC). TNBCs are highly aggressive, untreatable by hormone or ani-HER2 therapy, and overall have a poor survival. The genetic alterations behind TNBC development and progression are not well understood. Our goal is to understand the molecular mechanism(s) of TNBC with a view to develop suitable TNBC management strategies.
Endophilins are a family of proteins involved in clathrin mediated endocytosis, frequently altered in various cancers and implicated in biomarker development. One of the endophilins was found to be frequently altered in triple negative breast cancer and appeared to be involved in the regulation of cancer progression. Our laboratory is examining its potential role in triple negative breast cancer. We are also examining the potential role of miRNAs and mitochondrial energy reprogramming in triple negative breast cancer.
- Dasgupta S, Hoque MO, Upadhyay S, Sidransky D. Mitochondrial Cytochrome B Gene Mutation Promotes Tumor Growth in Bladder Cancer. Cancer Research, 68:700-706, 2008.
- Dasgupta S, Hoque MO, Upadhyay S, Sidransky D. Forced Cytochrome B gene mutation expression induces mitochondrial proliferation and prevents apoptosis in human uroepithelial SV-HUC-1 cells. Int J Cancer 125:2829-35, 2009.
- Dasgupta S, Yung RC, Westra WH, Rini DA, Brandes J, Sidransky D. Following mitochondrial footprints through a long mucosal path to lung cancer. PLoS One 4:e6533, 2009.D
asgupta S, Koch R, Westra WH, Califano JA, Ha PK, Sidransky D, Koch WM. Mitochondrial DNA mutation in margins and tumors of recurrent HNSCC patients. Can Prev Res 3:1205-11, 2010.
- Dasgupta S*, Dash R, Das SK, Sarkar D, Fisher PB*. Emerging strategies for the early detection and prevention of head and neck squamous cell cancer. J Cell Physiol. 22:467-73, 2012. (*Co-corresponding author).
- Dasgupta S*, Shao C, Keane TE, Duberow DP, Mathies RA, Fisher PB, Kiemeney LA, Sidransky D*. Detection of Mitochondrial DNA Alterations in Urine from Urothelial Cell Carcinoma Patients. (*Co-corresponding author). Int J Cancer 131:158-64, 2012.
- Dasgupta S*, Soudry E, Mukhopadhyay N, Shao C, Yee J, Lam S, Lam W, Zhang W, Gazdar AF, Fisher PB, David Sidransky*. Mitochondrial DNA Mutations in Respiratory Complex-I in Never-Smoker Lung Cancer Patients Contribute to Lung Cancer Progression and associated with EGFR gene mutation. (*Co-corresponding author). J Cell Physiol 227:2451-60, 2012.
- Dasgupta S*, Pal P, Shao C, Mukhopadhyay ND, Fu Y, Ratovitski EA, Moon C, Hoque MO, Fisher PB, Trink B*. A Single Nucleotide Polymorphism in human PIGK gene associates with low PIGK expression in colorectal cancer patients. (*Co-corresponding author). Int J Oncology 41:1405-10, 2012.
- Dasgupta S*, Jang JS, Shao C, Mukhopadhyay ND, Sokhi UK, Das SK et al. SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling. J Mol Med 91:381-93, 2013. (*Co-corresponding author).
- Dasgupta S. Mitochondrial Insult and Revenge in Tumorigenesis. J Clin Exp Oncol 1:1 doi: 10.4172/jceog (Editorial article), 2012.
- Dasgupta S*, Menezes ME, Das SK, Emdad L, Janijic A, Bhatia S, Mukhopadhyay ND, Shao C, Sarkar D, Fisher PB*. Novel Role of MDA-9/Syntenin in Regulating Urothelial Cell Proliferation by Modulating EGFR Signaling. Clinical Can Res 19:4621-33, 2013. (*Co-corresponding author).
- Das SK, Bhutia SK, Azab B, Kegelman TP, Peachy L, Santhekadur PK, Dasgupta S, Dash R, Dent P, Grant S, Emdad L, Pellecchia M, Sarkar D, Fisher P. MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma. Cancer Res 73:844-54, 2013.
- Dash R, Bhoopathi P,Das SK, Sarkar S, Emdad L, Dasgupta S, Sarkar D, Fisher PB. Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction.Cancer Res 74(2):563-74, 2014.
- Kegelman TP, Das SK, Hu B, Bacolod MD, Fuller CE, Menezes ME, Emdad L, Dasgupta S, Baldwin AS, Bruce JN, Dent P, Pellecchia M, Sarkar D, Fisher PB. MDA-9/syntenin is a key regulator of glioma pathogenesis. Neuro Oncol 16:50-61, 2014.